BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22161237)

  • 21. Clinical Value of Tumor Markers for Determining Cause of Pleural Effusion.
    Gu Y; Zhai K; Shi HZ
    Chin Med J (Engl); 2016 Feb; 129(3):253-8. PubMed ID: 26831224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
    Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
    Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.
    Salama G; Miédougé M; Rouzaud P; Mauduyt MA; Pujazon MC; Vincent C; Carles P; Serre G
    Br J Cancer; 1998; 77(3):472-6. PubMed ID: 9472646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
    Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
    Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor markers in pleural effusions.
    Topolcan O; Holubec L; Polivkova V; Svobodova S; Pesek M; Treska V; Safranek J; Hajek T; Bartunek L; Rousarova M; Finek J
    Anticancer Res; 2007; 27(4A):1921-4. PubMed ID: 17649796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
    Gaspar MJ; De Miguel J; García Díaz JD; Díez M
    Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-associated antigens in effusions of malignant and benign origin.
    Ammon A; Eiffert H; Reil S; Beyer JH; Droese M; Hiddemann W
    Clin Investig; 1993 Jun; 71(6):437-44. PubMed ID: 8353402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas.
    Chigira M; Shinozaki T
    Arch Orthop Trauma Surg; 1990; 109(5):247-51. PubMed ID: 1702981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer.
    Kandylis K; Vassilomanolakis M; Baziotis N; Papadimitriou A; Tsoussis S; Ferderigou A; Efremidis AP
    Ann Oncol; 1990 Nov; 1(6):435-8. PubMed ID: 2083187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential diagnosis of tuberculous and malignant pleural effusions: comparison of the Th1/Th2 cytokine panel, tumor marker panel and chemistry panel.
    Zhang J; Chen Y; He G; Jiang X; Chen P; Ouyang J
    Scand J Clin Lab Invest; 2020 Jul; 80(4):265-270. PubMed ID: 32108543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
    Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
    Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
    Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer.
    Gwak HK; Lee JH; Park SG
    Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.
    Ferroni P; Szpak C; Greiner JW; Simpson JF; Guadagni F; Johnston WW; Colcher D
    Int J Cancer; 1990 Sep; 46(3):445-51. PubMed ID: 2394511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tumor markers in pleural effusion of patients with lung cancer and patients with tuberculous pleurisy].
    Tada A; Kawai H; Matsumoto H; Kimura G; Okada C; Soda R; Takahashi K
    Nihon Kokyuki Gakkai Zasshi; 2002 Feb; 40(2):106-12. PubMed ID: 11974864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of three tumor markers determined in pleural effusions.
    Conejo JR; Benedito JE; Jimenez A; Menchen M; Cano J; Granizo V; Larrodera L
    Eur J Clin Chem Clin Biochem; 1996 Feb; 34(2):139-42. PubMed ID: 8833646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Conventional serum tumor markers in liver cancer. Retrospective analysis of 118 patients].
    Arias-Flórez JS; Martínez-Delgado AM; Alarcón-Tarazona ML; Insuasty-Enriquez JS; Díaz-Martínez LA
    Rev Med Chil; 2018 Dec; 146(12):1422-1428. PubMed ID: 30848745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
    Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
    Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
    Sagi-Dain L; Lavie O; Auslander R; Sagi S
    Int J Biol Markers; 2015 Jul; 30(3):e333-40. PubMed ID: 25704505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformation in patients with acute liver failure. A comparison with alpha-fetoprotein and carcinoembryonic antigen.
    Halme L; Kärkkäinen P; Isoniemi H; Mäkisalo H; von Bogulawski K; Höckerstedt K
    Scand J Gastroenterol; 1999 Apr; 34(4):426-31. PubMed ID: 10365905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.